Summary
Background. The database of genotypic drug resistance mutations in HIV-1 subtype B circulating in developed industrial countries has been well established; however, little is known regarding the prevalence of genotypic resistance patterns in patients harboring non-subtype-B HIV-1 variants in most Asian countries.
Objective. To characterize the polymorphisms and emergence of drug-resistance mutations, resistance to antiretroviral drugs in naïve and pretreated patients infected with HIV-1 CRF01_AE isolates in Fujian province, China.
Methods. HIV-1 pol amplicons from 52 pre- and 14 post-treatment samples were obtained by reverse transcription-polymerase chain reaction (RT-PCR) and sequencing. All of the 14 antiretroviral-treated patients were under a fixed regimen of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP), and they had been on treatment for a mean of 6 months (SD, 4 months).
The sequence data were analyzed using the Bioedit software, and the data regarding drug resistance mutations were obtained using the Stanford software (http://hivdb.stanford.edu).
Results. In comparison with the consensus sequence of B strains, the most common protease polymorphisms in HIV-1 CRF01_AE strains prevailing in Fujian Province, China, were I13V (76.9%), E35D (76.9%), M36I (100%), R41K (98.1%), H69K (90.4%), and L89M (96.2%). Protease mutations between CRF01_AE strains and B′ variants prevailing in China were observed. The proportion of substitutions L63P, A71T/V, V77I and I93L in subtype B′ sequences was considerably higher than in CRF01_AE viruses, while the proportion of L10I, M36I and K20R/I substitutions in subtype B′ sequences was relatively lower than in CRF01_AE strains. A high level of resistance to nucleoside reverse transcriptase inhibitors (NRTIs) (28.6%, 4/14) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (35.7%, 5/14) was found in treatment-experienced patients. High-level resistance to nevirapine (NVP) and lamivudine (3TC) was found in the stavudine/lamivudine/nevirapine (d4T/3TC/NVP) treatment regimen. The overall drug resistance rate was 42.9% (6/14), the resistance rates to two and to all three drugs under treatment were 14.3% (2/14) and 7.1% (1/14), respectively.
Conclusion. This study is the first report on polymorphisms and emergence of drug-resistance mutations in HIV-1 subtype CRF01_AE prevailing in China. These findings provide useful information on global HIV genetic variability and non-B drug resistance.
Article PDF
Similar content being viewed by others
References
JD Baxter JM Schapiro CA Boucher et al. (2006) ArticleTitleGenotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor Tipranavir J Virol 80 10794–10801 Occurrence Handle16928764 Occurrence Handle10.1128/JVI.00712-06 Occurrence Handle1:CAS:528:DC%2BD28XhtFygsb%2FK
V DeGruttola L Dix R D’Aquila et al. (2000) ArticleTitleThe relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan Antivir Ther 5 41–48 Occurrence Handle10846592 Occurrence Handle1:CAS:528:DC%2BD3cXktlSrsL4%3D
A Holguin C Sune F Hamy et al. (2006) ArticleTitleNatural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure J Clin Virol 36 264–271 Occurrence Handle16765636 Occurrence Handle10.1016/j.jcv.2006.05.001 Occurrence Handle1:CAS:528:DC%2BD28XntlGiu7w%3D
SL Jiang H Xing XF Si et al. (2006) ArticleTitlePolymorphism of the protease and reverse transcriptase and drug resistance mutation patterns of HIV-1 subtype B prevailing in China J Acquir Immune Defic Syndr 42 512–514 Occurrence Handle16810118 Occurrence Handle10.1097/01.qai.0000221688.69596.ba
VA Johnson F Brun-Vezinet B Clotet et al. (2006) ArticleTitleUpdate of the drug resistance mutations in HIV-1: fall 2006 Top HIV Med 14 125–130 Occurrence Handle16946457
R Kantor D Katzenstein (2004) ArticleTitleDrug resistance in non-subtype B HIV-1 J Clin Virol 29 152–159 Occurrence Handle14962783 Occurrence Handle10.1016/S1386-6532(03)00115-X Occurrence Handle1:CAS:528:DC%2BD2cXhtFWlt7g%3D
R Kantor DA Katzenstein B Efron et al. (2005) ArticleTitleImpact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration PLoS Med 2 IssueID4 e112 Occurrence Handle15839752 Occurrence Handle10.1371/journal.pmed.0020112
CF Pereira JT Paridaen (2004) ArticleTitleAnti-HIV drug development – an overview Curr Pharm Des 10 4005–4037 Occurrence Handle15579085 Occurrence Handle10.2174/1381612043382459 Occurrence Handle1:CAS:528:DC%2BD2cXhtVKjsL%2FI
D Pieniazek M Rayfield DJ Hu et al. (2000) ArticleTitleProtease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide AIDS 14 1489–1495 Occurrence Handle10983635 Occurrence Handle10.1097/00002030-200007280-00004 Occurrence Handle1:CAS:528:DC%2BD3cXmslWnsrc%3D
SY Rhee R Kantor DA Katzenstein et al. (2006) ArticleTitleHIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes AIDS 20 643–651 Occurrence Handle16514293 Occurrence Handle10.1097/01.aids.0000216363.36786.2b
RW Shafer (2006) ArticleTitleRationale and uses of a public HIV drug-resistance database J Infect Dis 194 S51–S58 Occurrence Handle16921473 Occurrence Handle10.1086/505356
WC Yam JHK Chen KH Wong et al. (2006) ArticleTitleClinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01 AE and subtype B patients receiving antiretroviral therapy in Hong Kong J Clin Virol 5 454–457 Occurrence Handle10.1016/j.jcv.2005.10.012
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liu, J., Yue, J., Wu, S. et al. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China. Arch Virol 152, 1799–1805 (2007). https://doi.org/10.1007/s00705-007-1019-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-007-1019-9